Conference Call with Indoco Remedies Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q4FY22 results: Q4FY22: Revenues of Indoco Remedies grew by 35.8% at Rs. 400.3 crores, as against Rs. 294.8 crores, same quarter last year. EBIDTA to net sales for the quarter is 20.1% at Rs. 80.5 crores, compared to 18.5% at Rs. 54.6 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 10.1% at Rs. 40.4 crores, compared to 8.4% at Rs. 24.9 crores, same quarter last year. FY22: The revenues grew by 23.4% at Rs. 1502.7 crores, as against Rs. 1217.4 crores, same period last year. EBIDTA to net sales for the period is 21.8% at Rs. 327.0 crores, compared to 18.4% at Rs. 223.6 crores, same period last year. For the period, the Profit After Tax to net sales is 10.3% at Rs. 154.5 crores, compared to 7.6% at Rs. 92.4 crores, same period last year. Commenting on the fourth quarter FY22 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “An excellent sales growth has resulted in an impressive financial performance inspite of various challenges, primarily higher input and freight costs.” Result PDF
Conference Call with Indoco Remedies Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.